Glycosylation is the most common post-translational modification of proteins, yet genes relevant to the synthesis of glycan structure and function are incompletely represented and poorly annotated on the commercially available arrays. To fill the need for expression analysis of such genes we employed the Affymetrix technology to develop a focused and highly annotated glycogene-chip representing human and murine glycogenes, including glycosyltranferases, nucleotide sugar transporters, glycosidases, proteoglycans and glycan-binding proteins. In this report the array has been used to generate glycogene expression profiles of nine murine tissues. Global analysis with a hierarchical clustering algorithm, reveals that expression profiles in immune tissues (thymus, spleen, lymph node and bone marrow) are more closely related, relative to those of non-immune tissues (kidney, liver, brain and testes). Of the biosynthetic enzymes, those responsible for synthesis of the core regions of N-and O-linked oligosaccharides are ubiquitously expressed, while glycosyltransferase that elaborate terminal structures are expressed in a highly tissue-specific manner, accounting for tissue and ultimately cell type-specific glycosylation. Comparison of gene expression profiles with MALDI-TOF profiling of N-linked oligosaccharides suggested that the α1-3
Introduction
Glycans occur as modifications of proteins (glycoproteins and proteoglycans) or lipids (glycosphingolipids) and form the core structure of the glycophospholipid (GPI) anchors by which many proteins are anchored to the membrane (Spiro 2002; Taylor et al. 2003) . Glycosylation is the most common form of post-translational modification of proteins, with over half of all proteins estimated to contain one or more glycan chains (Apweiler et al. 1999; Wells et al. 2003) . The roles of glycans are diverse. They contribute to the folding and conformational stability of many proteins (Bosques et al. 2004 ; Helenius et al. 2004; Wang et al. 1996) , mediate host-pathogen interactions and aspects of innate immunity (Colmenares et al. 2004; Karlsson 1995; Smith et al. 2004; Underhill 2003 ) , and serve as ligands for glycan-binding proteins that mediate cell trafficking, cell adhesion and cell signalling (Crocker 2002; Esko et al. 2002; Lowe 2002; Rabinovich et al. 2002; Wells et al. 2003) .
The glycome by definition comprises all glycan structures produced by an organism, while glycomics encompasses the study of glycan structure, biosynthesis and function . Although glycomics emerged as a separate discipline from proteomics, the two will become increasingly intertwined through the inextricable link between structure and function of their respective 'omes'. In contrast to the genomics and proteomics fields, in which the database and molecular tools are highly advanced, comparable tools for glycomics are in the formative stages (Cooper et al. 2003; Henrissat et al. 1996; Kanehisa et al. 2004; Kikuchi et al. 2003; Lutteke et al. 2004; Taylor et al. 2003) . Current glycan databases have assembled collections of thousands of unique structures, and the entire glycome, while certainly finite, will presumably number in the tens of thousands. In principle, since all the information necessary for synthesis of the glycome is contained within the genome, the current genome and proteome databases are relevant to glycan structure. However, glycan structure is determined by the concerted action of numerous genes that code for glycosyltransferases, glycosidases, and other enzymes that synthesize and remodel glycan chains, as well as accessory enzymes involved in the synthesis and transport of nucleotide sugars. In addition, some glycosyltransferases are known to be differentially expressed in various cells, contributing to cell-type specific glycosylation. Thus, prediction of glycan structures produced by a cell requires not only a knowledge of which of these enzymes is expressed, but also how they work together in a biosynthetic network to assemble glycans of defined structures resulting from the specificities of the enzymes themselves.
As a step towards obtaining global information relating to glycan biosynthesis, structure and function, we have constructed a focused gene microarray (Glycogenechip v1) using the Affymetrix technology. The chip contains families of 436 human and 285 murine genes, termed here 'glycogenes', coding for proteins responsible for glycan synthesis and glycan recognition, including glycosyltransferases and other glycan processing enzymes, enzymes relating to nucleotide synthesis and transport, proteoglycans, and glycan binding proteins. Unlike large scale commercial chips, it includes genes not currently represented and has been highly annotated by experts of each gene family, in order to facilitate interrogation of results with respect to gene function.
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In this report, the chip has been used to evaluate the expression of glycogenes in nine murine tissues to establish the degree to which the genes are detected, and determine if it can serve as a useful tool for analysis of glycan synthesis and function.
Remarkably, despite the fact that glycosyltransferases are expressed at only to 0.01-0.00001% of the cellular protein (Ju et al. 2002; Weinstein et al. 1982) , over 90 % of all glycogenes were detected in at least one tissue. Enzymes involved in the synthesis of core regions of glycan chains were constitutively expressed while those involving terminal regions were differentially expressed, providing global support for the concept that expression of these genes is a major factor in determining cell type specific glycosylation (Fukui et al. 2002; Sutton-Smith et al. 2002; Wang et al. 2002) . Moreover, some features of N-linked glycan profiles obtained by MALDI-TOF MS were reflected in the expression patterns of several glycosyltransferase genes. The results suggest that this highly annotated microarray will provide a useful tool for the analysis of the regulated synthesis of glycans and glycan function and several reports using the glycogene-chip array for analysis of limited sub-sets of genes have appeared (Brown et al. 2003; Smith et al. 2005) .
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Results
Glycogene expression profiles segregate tissues according to their biological function
Following optimization and validation of expression analysis using the glycogene-chip v1 (see Materials and Methods), we first surveyed nine murine tissues to evaluate the degree to which glycogenes are detected. In order to take into account biological variability as well as variability contributed by tissue collection procedures, array analysis was performed on RNA samples extracted from three independently prepared tissue samples. Each tissue sample was pooled from three age and sex matched littermates. The hybridization .CEL files and dChip expression values for each of the experiments performed are available at the CFG website and at GEO (http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE2781. 90% of all glycogenes were detected as present in at least one tissue. There are several possible reasons why a probe set would fail to indicate the presence of a transcript in any of the tissues surveyed, including lack or low level of transcript expression, and faulty probe set design caused by incomplete sequence information or ineffective probe selection.
To estimate the degree of relationship among the nine tissues in terms of glycogene expression, we extracted the probe sets falling in the glycosyltransferase, glycanbinding protein and proteoglycan categories and performed an unsupervised hierarchical cluster analysis for each of these groups of genes independently, using the glycogene array data for every replicate (Figure 1 ). The high correlation (short branches) within each of the three replicates for each tissue shows that there was little variability among samples. In the three cases, the clustering separates the immune tissues (thymus, spleen, lymph node and bone marrow) from the non-immune tissues (kidney, liver, brain and testes), with lung clustering with the immune tissues in the case of proteoglycans. In particular, secondary immune organs (lymph nodes and spleen) are more closely related between them than to primary organs (bone marrow and thymus).
We conclude that organs with similar functions have similar expression of glycogenes, both in terms of capability of synthesizing specific glycans and in terms of lectin expression, which implies the association of specific glycosylation patterns to their biological activities.
Expression patterns of glycan transferases involved in the synthesis of glycoprotein and glycolipid glycans
Core Sequences. Each class of glycoprotein and glycolipd glycans is characterized by common core structures, which are variously elongated and terminated, comprising the basis for structural diversity of glycans. (Tables I and II) . For this purpose, we have excluded other families of genes involved in glycan synthesis including glycosyltransferases involved in chain elongation (galactosyl-and Nacetylglucosaminyl-transferases) , and enzymes involved in the synthesis and transport of nucleotide sugars. A complete listing of the raw data can be found at http://www.functionalglycomics.org.
As summarized in Table I , enzymes involved in the synthesis of the core sequences of N-glycans are expressed at similar levels in every tissue, and can therefore be considered as "housekeeping" genes, in keeping with the fact that N-linked glycosylation is found in all eukaryotic cells.
The only sugar common to all major glycans of the 'mucin type' O-linked glycans is the GalNAcαThr/Ser linkage, which is synthesized by a family of polypeptide GalNAc transferases that has grown to nearly 20 members in recent years (Ten Hagen et al. 2003; Young et al. 2003) . Since the specificities of these enzymes in general have broad overlaps, one or more members of this family are sufficient to allow O-linked glycosylation. For the seven members of the family represented on this array, each tissue expresses 2-5 members. This is consistent with the ubiquitous expression of Olinked glycans given the overlapping specificity of these enzymes for initiation of Olinked glycosylation on the polypeptide chain (Bennett et al. 1996; Wandall et al. 1997; Zara et al. 1996) .
For glycolipds, two classes have been described that have in common the first sugar added to the ceramide (lipid) moiety. The glucosyl-ceramides are ubiquitously expressed in all cells with glycan chains of various size and diverse sequence. In contrast, galactosyl-ceramide, or cerebroside, is not extended except for addition of sulfate, and exhibits restricted expression to a few tissues (Varki 1999) . In keeping with the known distribution of these glycolipids, the glucosyltransferase that initiates the synthesis of the glucosylceramides is ubiquitously expressed, while the galactosyltransferase that forms the galactosylceramides is restricted to brain, kidney and testes (Table I) .
Terminal sequences. Biosynthetic elaboration of the cores structures to complete the terminal sequences gives rise to structural variation that differs from cell to cell. This is illustrated in Figure 3 for N-linked glycans, where the MALDI-MS profiles of the total extracted N-linked glycans of various tissues give a distinct spectrum of glycan structures. Each tissue exhibits terminal sequences that are a result of differential expression of the glycosyltransferases expressed in that cell. Not surprisingly, therefore, expression of glycan-transferases involved in terminal glycosylation exhibit highly variable expression from tissue to tissue, as illustrated in Table II As seen in the MALDI-TOF glycan profiles, sialylation of N-linked glycans is a predominant feature of all tissues examined, except kidney (Figure 3 ). The NeuAcα2-3/6Gal sequence that terminates these structures is accounted for by the expression of the ST3Gal and ST6Gal enzymes. No NeuAc-NeuAc linkages are evident in the MALDI-TOF glycan profiles in Figure 3 despite the expression of ST8Sia IV in thymus, spleen and lung. However, this enzyme exhibits highly restricted specificity for Nglycans of neural cell adhesion molecule (NCAM), and adds polymers of α2-8 linked sialic acids on these glycans. The absence of these structures is due either to a low or no expression of NCAM, or a low abundance and higher mass of polysialylated Nglycans. For O-linked glycans, each tissue expresses one or more of the ST3Gal I/II and the ST6GalNAc I-VI enzymes that form the NeuAcα2-3Galβ1-3(NeuAcα2-6)GalNAcαThr/Ser sequence, the most common O-linked glycan. Most siayltransferases involved in the synthesis of glycoprotein glycans are able to transfer sialic acids into corresponding glycans of glycolipids. It is notable that brain, unlike the other tissues, expresses high levels of the ST8Sial III and V enzymes responsible for the NeuAcα2-8NeuAc linkages in glycolipids of the ganglioside series which occur in brain at 10-100 fold higher levels than other tissues (Ando 1983; Kono et al. 1996; Yoshida et al. 1995) .
Fucosyltransferases comprise a family of about 13 members, which catalalyze the synthesis of the Fucα1-2Gal (Fut1 and Fut2), Fucα1-3GlcNAc (Fut3-Fut7 and Fut9), Fucα1-4GlcNAc (Fut3) and Fucα1-6GlcNAc (Fut8) linkages. Of the remaining four, the Pofut1 and Pofut2 enzymes are involved in formation of a novel O-linked glycan FucαThr in peptide motifs found in EGF domains, and no activity has yet been reported for Fut10 and Fut11 (Becker et al. 2003) . The Fucα1-6GlcNAc linkage is produced by Fut8, and is exclusively found in the core region of N-linked glycans attached to the GlcNAβAsn residue. As evident in Figure 3 , N-linked glycans of most tissues are 'core fucosylated' to some degree. Of the six tissues represented, the N-linked glycans of brain and kidney are predominately fucosylated (>90%), those of spleen and lung are 50-75% fucosylated, and those of thymus and liver are <50% fucosylated. As seen in Table II , expression of Fut8 is detected in all tissues except liver. The highest levels of expression in brain and kidney correspond to the high degree of fucosylation in these tissues. Lack of detection of Fut8 expression in liver is likely due to an expression level below the background signal, or that core fucosylation in this tissue is due instead to the existence of an as yet unidentified Fut8 homologue (Miyoshi 2002) .
While the Fucα1-6GlcNAc sequence is unique to N-linked glycans, the other three fucose-containing linkages are found in terminal sequences of both N-and O-linked glycoprotein and glycolipid glycans. In contrast to the virtually ubiquitous presence of core fucosylation, the terminal Fucα1-2Gal sequence is not detected in any of the Nglycan profiles in Figure 3 . Consistent with this observation, no expression was detected for the two fucosyltransferases capable of making this linkage, Fut1 and Fut2 (Table II) . However, terminal sequences with the Fucα1-3(4)GlcNAc linkage are a dominant terminal sequence in brain and kidney (Figure 3 ). Of the enzymes capable of forming these sequences, Fut9 is the only one expressed in brain and kidney, and is not expressed in any other tissue. Fut9 was previously demonstrated to be the enzyme responsible for the presence of Fucα1-3GlcNAc linkages in brain (Nishihara et al. 1999; Nishihara et al. 2003) . To determine if this was also the case in kidney, we performed immunohistochemistry analysis of kidney sections from wild-type and Fut9 knock-out mice, using an anti-stage-specific embryonic antigen 1 (SSEA-1) mAb that recognizes the Galβ1-4(Fucα1-3)GlcNAc (Lewis X) sequence as an antigenic epitope. As shown in Figure 4 , proximal tubules of the wild type kidney are strongly stained with anti-SSEA-1, while no staining is observed in the Fut9 knock-out mouse tissue, indicating a complete absence of the Fucα1-3GlcNAc. Western-blotting of glycoproteins size fractionated on SDS gels, and immuno-thin layer chromatography of glycolipids also showed staining of wild type glycoproteins and glycolipids, but not those from the Fut9 mouse. Thus, Fut9 appears to be the fucosyltransferase responsible for the synthesis of the Fucα1-3GlcNAc linkage in kidney.
Taken together, the results show that evaluation of glycosyltransferase expression data in a focused microarray will provide an important source of meta-data for investigating the regulation of glycan composition in mammalian tissues and cells.
Glycan-binding proteins
In addition to fulfilling structural roles, glycans function in many biological contexts involving recognition of glycan-encoded information by endogenous lectins or glycan binding proteins. Animal lectins fall into multiple structural categories of which the Ctype (calcium-dependent) and I-type (sialic acid immunoglobulin superfamily lectins) are two of the most diverse (Taylor et al. 2003) .
Examination of the expression data in Table III reveals multiple, contrasting patterns of expression. For example, a few of the C-type lectins appear to be ubiquitous or almost so. The observation that Dectin-1, the beta-glucan receptor of macrophages, and the macrophage mannose receptor are observed to be present in both immune and nonimmune tissues suggests that this pattern may be a hallmark of macrophage expression. Similarly, the broad distribution of P-selectin reflects its expression in endothelial cells in immune and non-immune tissues. In contrast, other genes are expressed in a very restricted set of tissues. For example, the surfactant proteins are only present in lung, brevican only in brain, and the mannose-binding proteins and galactose-binding clearance receptors, such as the hepatic asialoglycoprotein receptor and the Kupffer cell receptor, are liver-specific.
A group of genes restricted to the immune tissues is evident. L-selectin is constitutively and almost exclusively found on lymphocytes (Vestweber et al. 1999) and is thus present in tissues rich in immune cells, as are most of the proteins included in subcategory 5 of the C-type lectins, which are associated with T-cells (CD69), B-cells (CD72) or NK cells (Brown et al. 1997; Robinson et al. 1993 ). The various mannose-and galactose-binding type II receptors in sub-category 2 are the least well understood of the C-type lectins and their expression data provide new insights. For example, the macrophage asialoglycoprotein (galactose) receptor is known to be expressed on peritoneal and tumoricidal subsets of macrophages and on dendritic cells (Tsuiji et al. 2002) , but the high level in lymph nodes might suggest expression in further cell types.
On the other hand, the IgE Fc receptor (CD23) is expressed primarily on lymphocytes (Lüdin et al. 1987) , so expression restricted to the immune tissues is expected. DCimmunoreceptor has been described as a macrophage protein, as well as being on monocytes, B-cells and granulocytes (Bates et al. 1999) , and the data show the general distribution typical of macrophage expression. In contrast, mincle, which is usually described as a macrophage protein (Matsumoto et al. 1999 ) is restricted to immune tissues, which is not really expected and may be indicative of expression in another cell type such as dendritic cells. The main observation about the members of the DC-SIGN family is that the expression patterns for different family members seem to differ, suggesting that these proteins are involved in different functions or at least in the same function on different cell types. The finding of high levels of SIGN-R1 in spleen and lymph node corroborates recent descriptions of expression specifically in marginal zone macrophages of these two tissues (Geijtenbeek et al. 2002) .
The Siglecs group includes members of the Ig superfamily that bind sialic acid and are known to be expressed predominately by hematopoietic cells. Siglecs can bind either cis (on the same cell) or trans sialic acid and therefore are believed to regulate cell interaction. Moreover siglecs possess cytoplasmic ITIM motifs and can consequently be involved in regulating cell activation (Crocker 2002; Crocker et al. 2001; Nitschke et al. 2004 ). Consistent with these features, and conversely to the C-type lectins, all but one of the Siglecs detected by the array were found to be predominately expressed in the immune-tissues. In particular, CD22 (Siglec-2; predominately expressed B cells)
Siglec-E (neutrophils, NK cells and dendritic cells) and eosinophils) are predominately expressed in bone marrow, lymph nodes and spleen, and Siglec-F, selectively expressed in eosinophils, is expressed in bone marrow, lymph nodes and lung (Aizawa et al. 2003; Crocker 2002; Zhang et al. 2004) . The one exception is Siglec-4, or myelin-associated glycoprotein, which is expressed in glial cells of the central nervous system and, accordingly, was found to be restricted to brain (Crocker 2002) .
Proteoglycans
Proteoglycans consist of one or more glycosaminoglycan chains (heparan sulfate, chondroitin sulfate, or dermatan sulfate) attached to serine residues within a limited set of core proteins. Some proteoglycans are secreted and deposited in basement membranes (agrin and perlecan), whereas others make up the extracellular matrix surrounding connective tissue (e.g., the aggrecan family, the collagen proteoglycans, IX and XIV, as well as the small leucine rich proteoglycans, decorin, biglycan, lumican, fibromodulin and others). A number of membrane-associated proteoglycans exist as well, such as syndecans 1-4, the GPI-anchored glypicans 1-6, a CD44 variant called epican and others not represented on the array (e.g., NG2). Intracellular proteoglycans include serglycin, a proteoglycan found in storage granules, and invariant chain (CD74).
Glypican-1 tends to be expressed widely, whereas glypican-2 is expressed in the developing nervous system, and disappears upon completion of cell migration and axon outgrowth. Gypican-3 (OCI-5) is expressed during development in several tissues, but in the adult its expression is nearly restricted to the lung. Glypican-4 (K-glypican) is highly expressed in the mouse kidney and at low levels in adult brain and spleen.
Glypican-5 is highly expressed in the brain in adult animals. Glypican-6 is expressed most abundantly in the ovary, liver, and kidney, with lower levels of expression detected in other adult tissues. The microarray analysis shown in Table IV in general confirms these findings (De Cat et al. 2001; Filmus et al. 2001; Fransson 2003) .
As expected, the small leucine rich proteoglycans are expressed in non-lymphoid tissues, but the high level of expression in thymus, lymph node and spleen suggests that their expression may be tied to other functions. A similar argument can be made for collagen type XIV, which tends to be expressed in tissues containing fibrillar collagens Decorin exhibits growth inhibitory activity, possibly by way of binding TGF-β, and its high level of expression in thymus and lymph node suggests a potential role in immune cell maturation (Castagnola et al. 1992; Hocking et al. 1998; Iozzo 1998 ).
Not surprisingly, serglycin is expressed throughout the lymphoid tissues, most likely as a granular proteoglycan present in virtually all hematopoietic cells. CD44 (epican) and invariant chain are similarly expressed at high levels in lymphoid tissue, where they play a role in B-cell maturation. Syndecans are conspicuously missing from lymphoid tissues and cells, which may reflect their primary role in epithelial cells (Couchman 2003; Kolset et al. 1990; Schofield et al. 1999 ).
The heparan sulfate bearing proteoglycans play critical roles in embryonic development and physiology of adult animals, but their role in the immune system is unclear. Since many growth factors, chemokines and cytokines bind to heparan sulfate, they may play a role in matrix immobilization of these ligands or they may play direct roles in signaling reactions. The chondroitin sulfate bearing proteoglycans play important roles in matrix deposition and tissue architecture. Other roles in the immune system are not well studied. The microarray data suggests that additional studies are needed to understand how these proteoglycans participate in lymphoid (and myeloid) development, trafficking, and immune responses (Esko et al. 2001; Esko et al. 2002; Lander et al. 2000; Perrimon et al. 2000) .
Discussion
This study describes the establishment of a gene expression array, built with the Affymetrix platform, representing 436 human and 285 murine glycogenes and its use to investigate their expression patterns across nine murine tissues. Results cover the expression of many genes for which data in the literature are non-existent, scarce, or inconsistent. Observations derived from this analysis provide insights on the extent of transcriptional regulation of glycosylation. Since this study was completed, the Consortium for Functional Glycomics has developed an updated glycogene-chip v2 (Smith et al. 2005) , with 532 human and 470 murine glycogenes, that is available for use by request, and the gene list available online (http://www.functionalglycomics.org).
Despite the low levels at which most glycogenes are expressed, 90% were scored present in at least one tissue. On the other hand, only 15% were present in all tissues examined, highlighting the specificity of glycogene expression. Notably, the 
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Deleted: were As described in results, the validity of the gene expression data obtained with this chip is corroborated by the fact that the many of the previously described gene expression patterns have been confirmed by the array data. In some of the cases where a gene was not detected in a tissue where its expression is known, we could identify faults in the probe design mostly due to lacking sequence information of the 3' untranslated region, which can be extremely long for some genes, particularly glycosyltransferases. Because this problem was anticipated, an effort was made to include well-characterized ESTs or proprietary sequences provided by the CFG investigators. We believe that redesign of probe sets can resolve most of the problems of poor sensitivity. For genes in glycogene-chip v1 that gave no signal, 90% were detected following redesign of the probsets in glycogene-chip v2 (S. Head and T.
Gilmartin, unpublished). and in glycolipids are expressed in a highly tissue-specific manner, resulting in terminal glycosylation patterns as seen in the MALDI profiles for N-glycans. Use of this approach for linking glycosyltransferase expression to glycan structure was nicely exemplified in the present study by identifying Fut9 as the enzyme responsible for the synthesis of Lewis X structures in kidney. Such findings are consistent with the idea that terminal glycan sequences modulate the biological function of the protein to which they are attached. Therefore, the data support the increasing anecdotal evidence that differences between the glycome of diverse organs or cell types, or within the same cell type at different physiological states, largely depend on the concerted variation of glycosyltransferase gene expression levels.
The low expression levels of glycosyltransferases (Ju et al. 2002; Weinstein et al. 1982) , together with the fact that more than one enzyme can be responsible for the synthesis of the same glycan structure, has impaired a systematic analysis of glycoconjugates expression regulation. Microarray technology allows a big step forward in this direction. Enormous potential for discovery exists by performing meta-analysis of data sets for gene expression and glycan profiling by mass spectrophotometry techniques conducted on the same tissues and cell populations.
Materials and methods
Glycogene-chip v1 design
The glycogene-chip v1 oligonucleotide array is a custom Affymetrix GeneChip designed for the Consortium for Functional Glycomics (CFG) (www.functionalglycomics.org). The array contains probe sets targeted to 436 human and 285 murine glycogenes including glycosyltransferases, glycan binding proteins, proteoglycans and other genes involved in glycan synthesis and degradation. In addition, the chip contains probe sets for several other classes of genes including chemokines, cytokines, growth factors, interleukins, adhesion molecules and associated receptors. A set of probes for housekeeping genes was also included, as well as for 45 "spiked-in" genes from E. coli, B. subtilis, and Bacteriophage for quality control. In all there are a total of 624 mouse genes (752 probe sets) and 915 human genes (1017 probe sets) represented. The list of the glycogenes was compiled using information available on public databases such as UniGene (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=unigene) and CAZy (http://afmb.cnrs-mrs.fr/~cazy/CAZY/index.html), or using unpublished information provided by participating investigators of the Consortium for Functional Glycomics (CFG). The participating investigators also participated in extensive annotation of the list. The highly annotated gene list is available at www.functionalglycomics.org. This chip uses the standard Affymetrix gene expression detection system described by Lockhart et. al. (Lockhart et al. 1996) . Each transcript is targeted by one or more probe sets consisting of 11 probe pairs, each made of a Perfect Match (PM) and a Mismatch (MM) 25 base oligonucleotides. The chip contains two independent groups of probe
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sets, one for human and the other for mouse transcripts. The human probe sets were chosen, whenever possible, from the commercially available U133A,B GeneChip set, otherwise they were newly designed. Only 374 of the 436 human glycogenes are found or annotated on the Affymetrix U133A,B chip set, highlighting the incompleteness of this commercial array. In contrast, all mouse gene probe sets were custom designed specifically for the glycogene-chip v1. No attempt was made to screen for crosshybridization between mouse and human species during the probe design process.
Mice and tissue samples preparation
Mouse tissues comprising of liver, brain, kidney, spleen, thymus, lymph nodes, testis, lung and femurs for bone marrow preparation were harvested from 6-8 weeks old C57BL/6 male mice obtained from the Scripps Research Institute custom breeding core and sacrificed by cervical dislocation. The organs were snap-frozen immediately after harvesting. For bone marrow cell suspension preparation, the tissue was grinded between two frosted glass slides in RPMI medium and the obtained suspension clarified by filtering through cotton-plugged pipette before lysing erythrocytes by incubating at room temperature for 5 min in a solution of 150 mM ammonium chloride, 10 mM potassium carbonate, 0.1 mM EDTA, pH 7.2. All samples were stored at -80°C.
RNA preparation, labeling and chip hybridization
Total RNA was extracted with Trizol according to the manufacturer's suggested protocol 
Microarray data analysis
Present (P) and Absent (A) absolute calls were determined with the MAS 5.0 Affymetrix algorithm. The glycogenes were subsequently considered present (P) in one tissue if they had been assigned a present call in at least two of the three replicate samples. All
marginal (M) calls were interpreted as absent (A).
At present, there is no consensus on procedures for analyzing microarray data. We therefore evaluated several available methods seeking the most suitable for the glycogene-chip v1. To choose the signal generating algorithm, we evaluated Microarray Suite 5.0 (MAS 5.0, Affymetrix, Santa Clara, CA), dChip (Li et al. 2001) , and Robust Multiarray Analysis (RMA) (Irizarry et al. 2003) . To test the accuracy of these methods, we designed an experiment in which labeled RNAs from two mouse tissues, kidney and spleen, were prepared and mixed in a range of ratios and applied to replicate chips for analysis. The RNA preparations included 100% kidney (K), 100% spleen (S), 75%K 25%S, 50%K 50%S and 25%K 75%S. The design of this experiment was based on the assumption that transcript levels will change linearly while going from 100 percent of one tissue to the other. We observed a higher number of genes with Pearson's correlation coefficient closer to 1 when using dChip and RMA compared to MAS 5.0 ( Figure 5 ). This implies that by using the dChip and RMA signal algorithms, more of the variation between signal values could be accounted for by the biological variation (systematic mixing of the tissue types) than by technical variation. We decided to use the dChip PM-only model because of the general ease of use of the software at the time the analysis was performed. The dChip algorithm was therefore used to generate expression signal intensities and to normalize the dataset against the median-intensity array using the invariant-set strategy (Li et al. 2001) . A lack of consensus also exists with regard to the applicability of normalization methods for certain types of arrays, including focused arrays with potentially large proportions of genes exhibiting differential expression and where general statistical assumptions may be inaccurate (Hill et al. 2001; Hoffmann et al. 2002; Irizarry et al. 2003) . Because the glycogene v1 array is a small focused chip, our initial concern was that the invariant-set normalization method employed by dChip might prove inappropriate. Therefore, in order to assess the utility of this normalization strategy, we examined the signals generated by the pre-labelled "spike-in" controls which are routinely added to GeneChip hybridizaton cocktails (Eukaryotic hybridization controls, Affymetrix, Santa Clara, CA) in the nine different wild type tissues surveyed in this study. We tested the spike control signals (BioB, BioC, BioD, and Cre) and determined, by single factor ANOVA, that no significant difference existed across the nine wild type tissues (p > 0.05). We therefore concluded that this normalization method is appropriate for use with this chip.
The entire dataset has been submitted to the Gene Expression Omnibus (GEO) repository under accession number GSE2781. Genes differentially expressed across groups of replicate chips were identified by Significance of Microarray Analysis (SAM) (Tusher et al. 2001) . Following determination of the test statistic (q-value), the software performs a number of permutations that facilitates calculation of the false discovery rate (FDR), which is defined as the proportion of false positives among the significant genes (Broberg 2003) . Genes were identified as having a significant change in expression if their associated FDR was less than 1%. Unsupervised hierarchical clustering by sample was performed with BRB ArrayTools (http://linus.nci.nih.gov/BRBArrayTools.html) using the default settings for correlation and linkage.
Chip Performance Assessment
We first evaluated the performance of the glycogene-chip v1 against the existing commercial array Affymetrix U133A, in particular to determine the effects of the glycogene-chip size on individual gene expression measurements. To this end, we examined a subset of 835 human probe sets with identical probe sequences common to both the glycogene-chip v1 (1814 probe sets ) and the Affymetrix U133A chip (22,000+ probe sets ). We prepared RNA from the LS180 (human colon carcinoma) and U937
(human lymphoma) cell lines and hybridized each RNA preparation to three chips of each type. We compared the expression of the 835 probes subset across the two chip types for each cell line, using the MAS 5.0 software's algorithm for Present/Absent determination. The average percent present was 39.2 (+ 2.5) and 35.0 (+ 2.5) for the glycogene-chip v1 and the U133A chip, respectively. In addition, the chip background for both chip types was very similar (within 10%). These results suggest that, for the subset of genes found on both chips, the probe sets on the smaller glycogene-chip detect a higher percentage of transcripts as "Present" and perform at least as well as their counterparts on the large format U133A chip.
We then addressed experimental reproducibility and measured non-biological variability resulting from the sample preparation and labeling procedures. The experiment consisted of 36 separate array hybridizations using mouse brain RNA. In brief, RNA was prepared from four aliquots of a single homogenized mouse tissue sample by two different technicians. Three labeling reactions were performed for each RNA sample, and each labeling reaction was hybridized to three chips. Of the 33 chips that met our quality control specifications, we measured a mean r 2 (coefficient of determination) of 0.951 and a standard deviation of 0.060. In addition, hierarchical clustering analysis failed to elucidate a correlation associated with the technical parameters being tested (data not shown). These data suggests that the non-biological variability associated with sample RNA extraction, labeling, and hybridization is relatively low and, in our laboratory, has little systematic impact on the resulting microarray data. Based on these results, all subsequent experiments were performed with three independently prepared RNA preparations from each tissue and a single labeling was used to probe a single chip for each RNA sample.
N-glycan profiling
N-glycans were isolated from trypsinized detergent extracts of homogenized organs by peptide:N-glycanase F (PNGase F), permethylated by using the sodium hydroxide procedure and purified on a Sep-Pak C 18 cartridge as previously described (Sutton- Smith et al. 2000) . MALDI-MS instrumentation was the same as previously described (Kui Wong et al. 2003 ). Brain, kidney, liver, lung and spleen were analyzed at M-Scan Inc (West Chester, Pennsylvania) and thymus was analyzed at Imperial College London. Derivatised carbohydrate samples were dissolved in methanol/water 8:2 (v/v) and mixed in a 1:1 ratio with 10mg/ml 2,5-dihydroxybenzoic acid in 80:20 (v/v) methanol/water. 1.5μl aliquots were spotted onto a 100-well sample plate. Angiotensin I, adrenocorticotropic hormone (ACTH) fragment 1-17, ACTH fragment 18-39, ACTH fragment 7-38, were used for external calibration.
Immunohistochemical analysis of Lewis X expression in murine kidney
Expression of the 3-fucosyl-N-acetyllactosamine carbohydrate epitope was examined immunohistochemically with a mouse monoclonal antibody, SSEA-1 (IgM, Developmental Studies Hybridoma Bank at the University of Iowa, USA), at dilution of 1/500, using the method reported previously (Kudo et al. 2004) . Kidney tissues of wildtype and Fut9 knockout mice were fixed in 4% paraformaldehyde / phosphate-buffer saline (-) (w/v) and then embedded in paraffin. Immunostaining was performed using the streptavidin-biotin complex method (Elite ABC kit; Vectastain; Vector Laboratories) in deparaffinized sections. The peroxidase reaction was visualized with 3,3'-diaminobenzidine and nuclei were counterstained with hematoxylin.
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Fucosyl-transferases
The procedure for obtaining the intensity signals and all abbreviations and definition of Average Absent value provided in Table I . Classification of the carbohydrate-binding proteins is according to (Taylor, M.E. and Drickamer, K. 2003) . GenBank accession numbers correspond to the sequence that was used as a template for probe design. mRNA sequences for Siglec H and Siglec 10 were made available before publication by P. Crocker, University of Dundee, UK 
I-type
Siglecs Siglec- 1  -76  -------74  Siglec-2 (CD22)  -850  838  ------86  Siglec-3  ---------1018  Siglec-4  --------1213  231  Siglec-E  476  -371  ------282  Siglec-F  219  189  --305  ----242  Siglec-H  -761  -------445  Siglec-10  1089  1508  2013  ------797 Table IV . Tissue expression profiles of proteoglycan-related genes.
The procedure for obtaining the intensity signals and all abbreviations and definition of Average Absent value provided in Table I . GenBank accession numbers correspond to the sequence that was used as a template for probe design.
